BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
PB Fintech Ltd. reported revenue growth of 22% QoQ (our estimate: 9.3%) led by both core online and new initiatives business which grew 16%/44% QoQ driven by traction in protection offerings and strong rebound in point of sales person business (up 56% QoQ).
Adjusted Ebitda margin declined by 190 basis points QoQ to 1.6% (our estimate: 4.4%) due to higher marketing/team cost, traction in low contribution margin operations (POSP and health product (although net present value is very good in health).
PB Fintech remained confident of growing two- three times of industry growth and remained confident of positive profit after tax for FY24 and expects to 'Add' Rs. 2 billion plus of adjusted Ebitda every year hereon (retained Rs 10 billion PAT guidance for FY27).
Continued strength in both insurance and credit business, improving profitability reiterates our positive stance.
Maintain 'Buy' with target price of Rs. 1,100 (implies eight times on FY26E enterprise value/sales).
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

Four Indian B-Schools Make It To LinkedIn Global Top 20 MBA Rankings — Check Out Which Ones


'First 15 Minutes Reserved For...': IRCTC New Rule On Online Ticket Booking From October


Revised US Biosecure Act Could Unlock Opportunities For Indian Pharma Companies


Only Murders In The Building: 10 Thoughts From Season Five's Initial Musky Frames And Gory Twists
